Vol 12, No 5 (2016)

September/October

Open Access Open Access  Restricted Access Subscription or Fee Access

Table of Contents

Letters to the Editor

FDA and Abuse Deterrent Opioids: Don’t fix the blame. Fix the problem
Peter J. Pitts
PDF
307-309

Brief Communication

Transient low testosterone levels after oral hydrocodone may contribute to misdiagnosis of hypogonadism
Harry W. Daniell, MD
PDF
310-312

Articles

Clinically relevant concentrations of opioids for in vitro studies
Jason W. Boland, FRCP, PhD, A. Graham Pockley, PhD
PDF
313-321
Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release—Using criteria of health technology assessment
Johannes FX Hofmann, PhD, Arun Lal, MSc, MBA, Maike Steffens, Robert Boettger
PDF
323-331
Adherence to chronic opioid therapy prescribing guidelines in a primary care clinic
Cynthia Kay, MD, MS, Erica Wozniak, MS, Sarah Koller, DO, Audrey Ye, MD, Joanne Bernstein, MD
PDF
333-345
Assessment of acute pain in trauma—A retrospective prehospital evaluation
Stine Hebsgaard, MD, Anne Mannering, MD, Stine T. Zwisler, MD, PhD
PDF
347-353

Review Articles

Rhode Island Board of Medical Licensure and Discipline: Illustration of the disciplinary process as it pertains to cases involving opioid prescribing
James V. McDonald, MD, MPH
PDF
355-359

Ideas and Innovations

Coprescribing naloxone for patients on chronic opioid therapy: Lessons learned from a patient-safety initiative in primary care training sites
William Delaney, MD, Jessica Huff, MPH, MS, Sandra Mini, MD, Aiswarya Thomas, MD, Ralph Tremaglio, MD
PDF
360-366

Full Issue

Volume 12, Number 5; Journal of Opioid Management; September/October 2016
 
PDF
303-360